Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 670-686

  Inderberg Suso, Else Marit ^a   Trachsel, Sissel ^a   Lislerud, Kari ^a   Rasmussen, Anne Marie ^a   Gaudernack, Gustav ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Epitope spreading; hTERT; Non small cell lung cancer; Peptide vaccination; T helper cells; T cell epitopes

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS LIGAND; GAMMA INTERFERON; HLA A ANTIGEN; HLA B7 ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TELOMERASE; TEMOZOLOMIDE; TERTOMOTIDE;

ADULT; AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; INTERFERON PRODUCTION; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MEMORY T LYMPHOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR REGRESSION;

EID: 84878616949     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20426     Document Type: Article

References (48)

1. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality and cancer. Cold Spring Harb Symp Quant Biol 1994; 59:307-15; PMID:7587082; http://dx.doi. org/10.1101/SQB.1994.059.01.035.
2. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-5; PMID:7605428; http:// dx.doi.org/10.1126/science.7605428.
3. Shay JW. Telomerase in human development and cancer. J Cell Physiol 1997; 173:266-70; PMID:9365534; http://dx.doi.org/10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33 >3.0.CO;2-B.
4. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16:1217-22; PMID:9528864; http:// dx.doi.org/10.1038/sj.onc.1201882.
5. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67:4827-33; PMID:17510412; http://dx.doi. org/10.1158/0008-5472.CAN-06-3557.
6. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010; 12:31; PMID:20525204; http://dx.doi.org/10.1186/bcr2583.
7. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010; 16:154-63; PMID:20048334; http://dx.doi.org/10.1158/1078-0432.CCR-09-2850.
8. Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer 2010; 127:321-31; PMID:19908230.
9. Aloysius MM, McKechnie AJ, Robins RA, Verma C, Eremin JM, Farzaneh F, et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med 2009; 7:18; PMID:19298672; http://dx.doi.org/10.1186/1479-5876-7-18.
10. Chen DY, Vance BA, Thompson LB, Domchek SM, Vonderheide RH. Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. Cancer Biol Ther 2007; 6:1991-6; PMID:18087213; http://dx.doi.org/10.4161/cbt.6.12.5078.
11. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004; 10:828-39; PMID:14871958; http://dx.doi. org/10.1158/1078-0432.CCR-0620-3.
12. Wenandy L, Sørensen RB, Sengeløv L, Svane IM, thor Straten P, Andersen MH. The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 2008; 14:4-7; PMID:18172245; http://dx.doi. org/10.1158/1078-0432.CCR-07-4590.
13. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006; 95:1474-82; PMID:17060934; http://dx.doi. org/10.1038/sj.bjc.6603437.
14. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55:1553-64; PMID:16491401; http://dx.doi.org/10.1007/s00262-006-0145-7.
15. Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007; 67:10546-55; PMID:17974999; http://dx.doi.org/10.1158/0008-5472.CAN-07-2765.
16. + T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174:3798-807; PMID:15749921.
17. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004; 10:4688-98; PMID:15269141; http://dx.doi. org/10.1158/1078-0432.CCR-04-0325.
18. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17:4568-80; PMID:21586625; http://dx.doi.org/10.1158/1078-0432.CCR-11-0184.
19. Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, et al. Vaccination of patients with cutaneous melanoma with telomerase- specific peptides. Cancer Immunol Immunother 2011; 60:1553-64; PMID:21681371; http://dx.doi. org/10.1007/s00262-011-1061-z.
20. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009; 58:1609-26; PMID:19221745; http://dx.doi.org/10.1007/s00262-009-0670-2.
21. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95; PMID:11910899; http://dx.doi.org/10.1038/nri724.
22. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4:1009-15; PMID:14502286; http:// dx.doi.org/10.1038/ni978.
23. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003; 24:58-61; PMID:12547500; http:// dx.doi.org/10.1016/S1471-4906(02)00029-7.
24. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174:1783-6; PMID:15699103.
25. + T cells selectively kill B lymphocytes. Blood 2006; 107:3925-32; PMID:16418326; http://dx.doi.org/10.1182/blood-2005-11-4502.
26. + T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fasdeficient target cells. J Immunol 2003; 170:2205-13; PMID:12574394.
27. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60:809-18; PMID:21365467; http://dx.doi. org/10.1007/s00262-011-0991-9.
28. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 2003; 9:4743-55; PMID:14581345.
29. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi. org/10.1038/44385.
30. + T lymphocytes. J Immunol 2007; 178:4112-9; PMID:17371966.
31. Ben-Smith A, Gorak-Stolinska P, Floyd S, Weir RE, Lalor MK, Mvula H, et al. Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus? BMC Infect Dis 2008; 8:139-48; PMID:18922182; http://dx.doi. org/10.1186/1471-2334-8-139.
32. Harrington LE, Janowski KM, Oliver JR, Zajac AJ, Weaver CT. Memory CD4 T cells emerge from effector T-cell progenitors. Nature 2008; 452:356-60; PMID:18322463; http://dx.doi.org/10.1038/ nature06672.
33. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847-57; PMID:21918169; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385.
34. + T cell-mediated cytotoxicity. J Immunol 1999; 162:2639-47; PMID:10072506.
35. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5:1289-97; PMID:10389911.
36. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624-32; PMID:12039923; http://dx.doi. org/10.1200/JCO.2002.06.171.
37. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/ neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685-92; PMID:19720923; http://dx.doi.org/10.1200/ JCO.2008.20.6789.
38. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002; 168:5954-8; PMID:12023402.
39. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 2001; 167:98-106; PMID:11418637.
40. Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011; 128:1120-8; PMID:20473937; http://dx.doi. org/10.1002/ijc.25449.
41. + T cell repertoire in the transition from effector to memory. Immunity 2008; 28:533-45; PMID:18356084; http://dx.doi.org/10.1016/j.immuni. 2008.02.014.
42. Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur J Immunol 2011; 41:3187-97; PMID:21898380; http://dx.doi.org/10.1002/ eji.201141452.
43. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651-67; PMID:20156973; http:// dx.doi.org/10.1084/jem.20091921.
44. + T cells. J Immunol 2008; 180:3122-31; PMID:18292535.
45. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510-3; PMID:19898495; http://dx.doi.org/10.1038/ nature08511.
46. Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med (Berl) 2003; 81:43-50; PMID:12545248.
47. Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumormRNA for melanoma vaccination. Cancer Gene Ther 2005; 12:579-91; PMID:15818380; http://dx.doi. org/10.1038/sj.cgt.7700837.
48. Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009; 340:11-24; PMID:18929568; http://dx.doi. org/10.1016/j.jim.2008.09.014